TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact
背景

TST010

Undisclosed
Target:
Undisclosed
Indication:
Solid tumors
Project Status:
Preclinical

Tumor-infiltrating regulatory T cells (Tregs) function to suppress T effectors, and its presence was reported to correlate with tumor progression and a worsening prognosis in many cancers.

TST010 displayed potent and selective Treg depleting activity and can liberate T effectors in tumor microenvironment to induce immune mediated killing of cancer cells in preclinical tumor models.

TOP